{"symbol":"REGN","fiscalQuarter":"Q3-2018","reportDate":"2018-11-06","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q3-2018","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 0.76%","keyNumbers":[{"metric":"EPS","actual":"$5.87","expected":"N/A","surprise":"+9.86%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted strong performance in key product areas.","They emphasized ongoing investment in research and development."],"summary":"Overall, management expressed confidence in the company's growth trajectory. They noted the importance of innovation and product pipeline."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance indicates effective cost management and possibly robust sales in their product lines. The stock's modest increase of 0.76% reflects investor confidence in the company's current trajectory despite the lack of revenue details and guidance. The positive surprise in EPS suggests that the company is performing better than expected in terms of profitability.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q3 2018 earnings: EPS beat by 9.86%. Stock up 0.76%. Full breakdown."}}